ADCT-701 is under clinical development by ADC Therapeutics and currently in Phase I for Adrenocortical Carcinoma (Adrenal Cortex Cancer). According to GlobalData, Phase I drugs for Adrenocortical Carcinoma (Adrenal Cortex Cancer) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ADCT-701’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ADCT-701 overview
ADCT-701 (LIV-1205) is under development for the treatment of neuroendocrine carcinoma and adrenocortical carcinoma. It is a monoclonal antibody conjugate developed based on ADLib system (Autonomously Diversifying Library system) and pyrrolobenzodiazepine (PBD) warhead technology. This technology develops antibody drug conjugated by linking pyrrolobenzodiazepine (PBD) dimers with tumor specific antibody. The drug candidate acts by targeting delta-like 1 homolog (DLK1). It is administered through intravenous route.
It was also under development for the treatment of solid tumors, hepatocellular carcinoma, small cell lung cancer and neuroblastoma
ADC Therapeutics overview
ADC Therapeutics is a commercial-stage biotechnology company that develops antibody-drug conjugates (ADCs) to treat hematologic malignancies and solid tumors. It develops drugs by using PBD dimer technology. The company’s pipeline products include loncastuximab tesirine-lpyl, an ADC composed of a humanized monoclonal antibody that binds to human CD19 and treats B-cell lymphoma; ADCT-602 is a monoclonal antibody that binds to CD22 targets acute lymphoblastic leukemia; ADCT-601 (mipasetamab uzoptirine) is a humanized monoclonal antibody that binds to human AXL treats various solid tumors; and Claudin-6, NaPi2b and PSMA. The company operates through its subsidiaries in the US, the UK and the Netherlands. ADC Therapeutics is headquartered in Lausanne, Switzerland.
For a complete picture of ADCT-701’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
